Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis

This publication has 16 references indexed in Scilit:

• Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected?
  Progress in Cardiovascular Diseases, 2010
• Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
  Journal of Clinical Oncology, 2010
• Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment
  American Heart Journal, 2010
• Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
  Cancer, 2005
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
  Circulation, 2004
• Congestive heart failure in patients treated with doxorubicin
  Cancer, 2003
• Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
  Annals of Oncology, 2002
• Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
  JACC, 2000
• Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
  Journal of Clinical Oncology, 1998
• Daunomycin-induced cardiotoxicity in children and adults
  The American Journal of Medicine, 1977